Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...

Although it often affects people later in life, it is not uncommon for people 40 and older to be affected ... such as Avastin, Lucentis, and Eylea. These drugs work by blocking VEGF, a protein that ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

The UK Top 40 is broadcast on BBC Radio 1, the Top 100 is published exclusively on OfficialCharts.com. View the biggest songs of 2024 so far.

BERLIN (Reuters) - Germany's Bayer (OTC:BAYRY) said on Sunday it was starting a Phase III study program to investigate the ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...